SGP (SpyGlass Pharma) NonCurrent Deferred Revenue: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $26.39
! 1 Warning Sign
View Full Analysis

What is SpyGlass Pharma NonCurrent Deferred Revenue?

SpyGlass Pharma SGP -1.67% 12 NonCurrent Deferred Revenue is $0.00 Mil as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

SpyGlass Pharma's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0.00 Mil.

SpyGlass Pharma NonCurrent Deferred Revenue Related Terms

SpyGlass Pharma NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma NonCurrent Deferred Revenue Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
0.00 0.00 0.00

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
SGP
12GF Score
SpyGlass Pharma Inc SGP
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
SpyGlass Pharma (SGP) has a NonCurrent Deferred Revenue of $0.00 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on SpyGlass Pharma and its competitors.
Is SpyGlass Pharma's NonCurrent Deferred Revenue too high?
SpyGlass Pharma's current NonCurrent Deferred Revenue is $0.00 Mil. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's NonCurrent Deferred Revenue compare to RIGL and NGNE?
SpyGlass Pharma's NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current NonCurrent Deferred Revenue of $0.00 Mil. The current NonCurrent Deferred Revenue is $0.00 Mil. SpyGlass Pharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current NonCurrent Deferred Revenue is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.39
Price